S'abonner

Sex differences in management and outcomes of patients with stable symptoms suggestive of coronary artery disease: Insights from the PROMISE trial - 20/02/19

Doi : 10.1016/j.ahj.2018.11.002 
Neha J. Pagidipati, MD, MPH a, , Adrian Coles, PhD a, Kshipra Hemal, BS a, Kerry L. Lee, PhD a, Rowena J. Dolor, MD, MHS a, b, Patricia A. Pellikka, MD c, Daniel B. Mark, MD a, Manesh R. Patel, MD a, Sheldon E. Litwin, MD d, Melissa A. Daubert, MD a, Svati H. Shah, MD a, b, Udo Hoffmann, MD e, Pamela S. Douglas, MD a
on behalf of the

PROMISE Investigators

a Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 
b Department of Medicine, Duke University School of Medicine, Durham, NC 
c Mayo Clinic, Rochester, MN 
d Department of Medicine, Medical University of South Carolina, Charleston, SC 
e Massachusetts General Hospital, Harvard Medical School, Boston, MA 

Reprint requests: Neha J. Pagidipati, MD, MPH, Duke Clinical Research Institute, Duke University School of Medicine, PO Box 17969, Durham, NC 27715.Duke Clinical Research Institute, Duke University School of MedicinePO Box 17969DurhamNC27715

Abstract

Background

Although sex differences exist in the management of acute coronary syndromes, less is known about the management and outcomes of women and men with suspected coronary artery disease being evaluated with noninvasive testing (NIT).

Methods

We investigated sex-based differences in NIT results and subsequent clinical management in 4,720 women and 4,246 men randomized to CT angiography versus stress testing in the PROMISE trial. Logistic regression models assessed relationships between sex and referral for catheterization, revascularization, and aspirin or statin use. Cox regression models assessed the relationship between sex and the composite of all-cause death, myocardial infarction, or unstable angina.

Results

Women more often had normal NITs than men (61.0% vs 49.6%, P < .001) and less often had mild (29.3% vs 35.4%, P < .001), moderate (4.0% vs 6.8%, P < .001), or severe abnormalities (5.7% vs 8.3%, P < .001) found on NIT. Women were less likely to be referred for catheterization than men (7.6% vs 12.6%, adjusted OR 0.75 [0.62-0.90]; P = .002). Of those who underwent catheterization within 90 days of randomization (358 women, 534 men), fewer women than men had obstructive coronary artery disease (40.8% vs 60.9%, P < .001). At a 60-day visit, women were significantly less likely than men to report statin use when indicated (adjusted OR 0.81 [0.73-0.91]; P < .001) but were similarly likely to report aspirin use when indicated (adjusted OR 0.78 [0.56-1.08]; P = .13). Over a median follow-up of 25 months, women had better outcomes than men (adjusted OR 0.73 [0.57-0.94]; P = .017).

Conclusions

Although women more frequently had normal NITs compared with men, those with abnormalities on NIT were less likely to be referred for catheterization or to receive statin therapy. The high rates of negative NIT in women, coupled with the better outcomes compared with men, strongly support the need for a sex-specific algorithm to guide NIT and chest pain management.

Le texte complet de cet article est disponible en PDF.

Plan


 Philip F. Binkley, MD, MPH, served as guest editor for this article.
 Clinical Trial Registration: ClinicalTrials.gov # NCT01174550.


© 2018  Elsevier Inc. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 208

P. 28-36 - février 2019 Retour au numéro
Article précédent Article précédent
  • Attitudes and considerations of patients with ST-elevation myocardial infarction toward participation in randomized clinical trials
  • Christoffer Polcwiartek, Pia Behrndtz, Ann Hass Andersen, Marianne Bregendahl, Helle Pedersen Hald, Svend Eggert Jensen
| Article suivant Article suivant
  • Accelerated coronary atherosclerosis not explained by traditional risk factors in 13% of young individuals
  • Trajen Head, Lisa Henn, Victor P. Andreev, Edward E. Herderick, Sapna K. Deo, Sylvia Daunert, Pascal J. Goldschmidt-Clermont

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.